We unite the leading researchers and cancer specialists of Fred Hutch and UW Medicine so you can take part in Merkel cell carcinoma (MCC) research through clinical trials not available everywhere.

Understanding the stages of Merkel cell carcinoma (MCC) helps you and your physician know how far the cancer has grown or spread. These stages also guide decisions about the treatment options your ...

Please provide your email address to receive an email when new articles are posted on . 65.1% and 63.8% of Merkel cell carcinoma cases were attributed to ambient ultraviolet radiation exposure and ...

Please provide your email address to receive an email when new articles are posted on . Merkel cell carcinoma is often diagnosed after metastasis to other organs. However, new findings show those with ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to ...

Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was not significant. HealthDay News — For patients with resected Merkel cell carcinoma (MCC), adjuvant ...

Megha Padi, PhD, is a member of the University of Arizona Cancer Center and an assistant professor at the U of A College of Science. Merkel cell carcinoma is a rare but fast-growing neuroendocrine ...

Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. Researchers evaluated 38,020 MCC cases (38% ...

The detection of metastases in Merkel cell carcinoma (MCC) requires additional testing, such as pancytokeratin (panCK) or CK20, with no guarantee of success. Recent findings have identified ...

Patients with resected Merkel cell carcinoma residing in Medicaid expansion states had greater survival rates than those in nonexpansion states.